Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite

Clinical Pharmacokinetics

Volumn 49, Issue 10, 2010, Pages 693-702

  Narwal, Rajesh ^a   Akhlaghi, Fatemeh ^a   Åsberg, Anders ^b   Hermann, Monica ^b   Rosenbaum, Sara E ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

adverse drug reactions; antihyperlipidaemics; atorvastatin; HMG CoA reductase inhibitors; metabolism; metabolites; pharmacokinetic modelling; pharmacokinetics; population pharmacokinetics; rhabdomyolysis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; ATORVASTATIN LACTONE; DRUG METABOLITE; LACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GENETIC POLYMORPHISM; HUMAN; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MALE; MYOPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AREA UNDER CURVE; ATHEROSCLEROSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRROLES;

EID: 77956379283     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11535980-000000000-00000     Document Type: Article

References (37)

1. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease: I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973 Jul; 52 (7): 1533-1543
2. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and ther-apeutic potential in the management of hyperlipidaemias. Drugs 1997; 53 (5): 828-847 (Pubitemid 27195013)
3. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39 (12): 3297-3302
4. Bakker-Arkema RG, Best J, Fayyad R, et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis 1997; 131 (1): 17-23
5. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med 2001; 5 (4): 378-387
6. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI. Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 222-228
7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003 Apr 2; 289 (13): 1681-1690
8. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdo-myolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292 (21): 2585-2590
9. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35 (9): 1096-1107
10. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhab-domyolysis. Ann Pharmacother 2002; 36 (2): 288-295
11. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42 (13): 1141-1160
12. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 0; 17 (2): 209-215
13. Gibson DM, Stern R, Abel RB. Absolute bioavailability ofatorvastatin in man [abstract]. Pharm Res 1997; 14: S253
14. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 0; 28 (11): 1369-1378
15. Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 3; 10 (10): 1461-1465
16. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30 (5): 505-512
17. Prueksaritanont T, Ma B, Fang X, et al. Beta-oxidation of simvastatin in mouse liver preparations. Drug Metab Dispos 2001; 29 (10): 1251-1255
18. Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q andR hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28 (11): 1335-1342
19. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is un-changed but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006; 79 (6): 532-539
20. Skottheim IB, Gedde-Dahl A, Hejazifar S, et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008; 33 (4-5):25
21. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33 (4): 537-546
22. Lau YY, Huang Y, Frassetto L, et al. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81 (2): 194-204
23. Lau YY, Okochi H, Huang Y, et al. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006; 316 (2): 762-771
24. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359 (8): 789-799
25. Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010 Jan; 87 (1): 65-73
26. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009; 86 (2): 197-203
27. Stern RH, Yang BB, Horton M, et al. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997; 37 (9): 816-819
28. Schwartz JB, Verotta D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther 2009; 86 (5): 497-502
29. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25%to60%inpatients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15 (5): 678-682
30. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hyper-triglyceridemia. JAMA 1996; 275 (2): 128-133
31. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharm-acokinetics of atorvastatin in humans. J Clin Pharmacol 1996; 36 (3): 242-246
32. Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005; 78 (2): 154-167
33. Hermann M, Christensen H, Reubsaet JL. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 2005; 382 (5): 1242-1249
34. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2006
35. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30 (5): 329-332
36. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmaco-kinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997; 33 (5): 313-327
37. Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004; 76 (4): 388-391